Recommendations for the use of inactivated influenza vaccines and other preventive measures.
Lavanchy
D
D
WHO, Epidemic Disease Control, Department of Communicable Disease Surveillance and Response, Geneva, Switzerland.
Osterhaus
A D
AD
D000998:Antiviral Agents / Q000494:pharmacology; D006801:Humans; D007252:Influenza Vaccines / Q000009:adverse effects / Q000494:pharmacology* / Q000592:standards; D007251:Influenza, Human / Q000517:prevention & control*; D011634:Public Health; D012307:Risk Factors; D012449:Safety; D012621:Seasons; D014611:Vaccination / Q000191:economics; D014613:Vaccines, Attenuated / Q000494:pharmacology; D015164:Vaccines, Inactivated / Q000009:adverse effects / Q000494:pharmacology / Q000592:standards; D014944:World Health Organization
D000998:Antiviral Agents; D007252:Influenza Vaccines; D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated